Influence of obesity and cardiometabolic makers on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in adolescents: The healthy young cross-sectional study

Lipids in Health and Disease

Volumn 12, Issue 1, 2013, Pages

  Da Silva, Isis T ^a   De Souza Timm, Anelise ^a   Damasceno, Nágila R T ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Faculdade Saude Publica   (Brazil)

Author keywords

Adolescent; Cardiovascular risk; Lp PLA2; Obesity

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ARTICLE; BODY COMPOSITION; BODY MASS; CARDIOVASCULAR RISK; CHILD; ENZYME ACTIVITY; FAT MASS; FEMALE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OBESITY; SCHOOL CHILD; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADOLESCENT; ANTIBODIES, ANTIPHOSPHOLIPID; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY COMPOSITION; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INSULIN; MALE; OBESITY; RISK FACTORS; WAIST CIRCUMFERENCE; YOUNG ADULT;

EID: 84873743116     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-12-19     Document Type: Article

References (47)

1. "Prevalence of obesity among children and adolescents: United States, trends 1963-1965 through 2007-2008." Ogden, Cynthia, and Margaret Carroll, Centers for Disease Control and Prevention. National Center for Health Statistics, Atlanta 2010 http://www.cdc.gov/nchs/data/hestat/obesity-child-07- 08/obesity-child-07-08.htm
2. IBGE, Antropometria e Análise do estado nutricional de crianças e adolescentes no Brasil. Pesquisa de orçamentos familiares, 2002-2003 2006 http://www.ibge.gov.br/home/presidencia/noticias/ noticia-visualiza.php?id-noticia=1699&id-pagina=1 2010
3. Obesity in the new millennium. Fiedman JM, Nature 2000 404 632 634 10766249
4. Inflammation: the link between insulin resistance, obesity and diabetes. Dandona P, Aljada A, Bandyopadhyay A, Trends Immunol 2004 25 4 7 10.1016/j.it.2003.10.013 14698276 (Pubitemid 38032801)
5. Successful weight maintenance preserves lower levels of oxidized LDL achieved by weight reduction in obese men. Linna MS, Borg P, Kukkonen-Harjula K, Foglholm M, Nenonem A, Ahotupa M, Vasankari TJ, Int J Pediatr Obes 2007 31 245 253 10.1038/sj.ijo.0803413 (Pubitemid 46183129)
6. Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease. Holvoet P, Verh K Acad Geneeskd Belg 2008 70 193 219 18669160
7. The Burden of Diabetes Mellitus Among US Youth: Prevalence Estimates From the SEARCH for Diabetes in Youth Study. SEARCH for Diabetes in Youth Study Group, Pediatrics 2006 118 1510 1518 17015542
8. Prevalence of Abnormal Lipid Levels among Youths-United States, 1999-2006. CDC(Center for Disease Control), Weekly 2010 59 29 64
9. The role of abdominal obesity and weight gain since adolescence in early atherosclerosis. Celik T, Iyisoy A, Yuksel UC, Isik E, Int J Cardiol 2009 132 263 295 10.1016/j.ijcard.2007.05.094 17651829
10. Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. The Lp-PLA2 Studies Collaboration, Lancet 2010 375 1536 1544 20435228
11. Plasma PAF-acetylhydrolase: An unfulfilled promise? Karabina S, Ninio E, Biochim Biophys Acta 2006 1761 1351 1358 10.1016/j.bbalip.2006.05.008 16807087 (Pubitemid 44738700)
12. Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome. Rizos E, Tambaki AP, Gazi I, Tselepis AD, Elisaf M, Prostaglandins Leukot Essent Fatty Acids 2005 72 203 209 10.1016/j.plefa.2004. 10.021 15664305 (Pubitemid 40139085)
13. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor acetylhydrolase. Tselepis AD, Chapmam MJ, Atherosclerosis 2002 3 57 68 10.1016/S1567-5688(02)00045-4 12573364 (Pubitemid 38234487)
14. Electronegative low-density lipoprotein. Sánchez-Quesada JL, Benítez S, Ordóñez-Llanos J, Curr Opin Lipidol 2004 15 329 335 10.1097/00041433-200406000-00014 15166790 (Pubitemid 38716567)
15. The epidemiology of Lp-PLA2: Distribution and correlation with cardiovascular risk factors in a population-based cohort. Persson M, Nilsson J, Nelson J, Hedblad B, Berglund G, Atherosclerosis 2007 190 388 396 10.1016/j.atherosclerosis.2006.02.016 16530769 (Pubitemid 46074030)
16. Ratio of LDL- to HDL-Associated Platelet-Activating Factor Acetylhydrolase may be a Marker of Inflammation in Patients With Paroxysmal Atrial Fibrillation. Okamura K, Miura S, Zhang B, Uehara Y, Matsuo K, Kumagai K, Saku K, Circ J 2007 71 214 219 10.1253/circj.71.214 17251670 (Pubitemid 46182695)
17. Lipoprotein-Associated Phospholipase A2 as a Novel Risk Marker for Cardiovascular Disease. Madjid M, Ali M, Willerson JT, Tex Heart Inst J 2010 37 25 39 20200624
18. WHO (World Health Organization), Nutrition in adolescence Issues and Challenges for the Health Sector WHO, Geneva 2005
19. IV Diretrizes Brasileiras de Hipertensão Arterial. Sociedade Brasileira de Hipertensão, Arq Bras Cardiol 2004 82 IV 7 14 15107944
20. Establishing a standard definition for child overweight and obesity worldwide: international survey. Cole T, Bellizze MC, Flegal KM, Dietz WH, BMJ 2000 320 1 6 10.1136/bmj.320.7226.1 10617503
21. Body mass index cut offs to define thinness in children and adolescents: international survey. Cole T, Flegal KM, Nicholls D, Jackson AA, BMJ 2007 335 1 9 10.1136/bmj.39262.506528.47 17615183 (Pubitemid 47066887)
22. UNIFESP-Nutrition Data System NDS® Food and Nutrient Database version 35 Regent of the University of Minnesota 2005 http://www.unifesp.br/dis/ produtos/nutwin/index.htm
23. Willett W, Stampfer M, Implications of total energy intake for epidemiologic analysis. Nutritional epidemiology Oxford University Press, New York 2 1998
24. Energy adjustment the concepts underlying the debate. Mackerras D, J Clin Epidemiol 1996 49 957 962 10.1016/0895-4356(96)00142-4 8780602 (Pubitemid 26319027)
25. A Semiparametric Transformation Approach to estimating Usual Daily Intake distributions. Nusser SM, Carriquiry AL, Dodd KW, et al. J Am Stat Assoc 1996 91 1440 1449 10.1080/01621459.1996.10476712
26. Variations in pattern of pubertal changes in girls. Marshall WA, Arch Dis Childhood 1969 44 291 303 10.1136/adc.44.235.291
27. Variations in pattern of pubertal changes in boys. Marshall WA, Tanner JM, Arch Dis Childhood 1970 44 13 23
28. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Friedewald WT, Levy RI, Fredrickson DS, Clin Chem 1972 18 499 502 4337382
29. Rapid, Simple Laser-Light-Scattering Method for HDL Particle Sizing in Whole Plasma. Lima ES, Maranhão RC, Clin Chem 2004 50 6 1086 1088 10.1373/clinchem.2004.032383 15161731 (Pubitemid 38725806)
30. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in men. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC, Diabetologia 1985 28 412 419 10.1007/BF00280883 3899825 (Pubitemid 15018832)
31. Detection of electronegative low density lipoprotein (LDL) in plasma and atherosclerotic lesions by monoclonal antibody-based immunoassays. Damasceno N, Sevanian A, Apolinário E, Oliveira J, Fernandes I, Abdalla D, Clin Biochem 2006 39 28 38 10.1016/j.clinbiochem.2005.09.014 16310760 (Pubitemid 43005267)
32. Soy isoflavones reduce electronegative low density lipoprotein (LDL-) and anti-LDL- autoantibodies in experimental atherosclerosis. Damasceno NRT, Apolinario E, Fernandes I, Flauzino FD, Abdalla DSP, Eur J Nutr 2007 46 125 132 10.1007/s00394-006-0640-9 17265172 (Pubitemid 46481363)
33. Waist circumference predicts increased cardiometabolic risk in normal weight adolescent males. Taylor SA, Hergenroeder AC, Int J Pediatr Obes 2012 6 307 311
34. Dietary, lifestyle, and clinical predictors of lipoprotein-associated phospholipase A2 activity in individuals without coronary artery disease. Hatoum IJ, Nelson JJ, Cook NR, Hu FB, Rimm EB, Am J Clin Nutr 2010 91 786 793 10.3945/ajcn.2009.28870 20107195
35. Atorvastatin Preferentially Reduces LDL-Associated Platelet-Activating Factor Acetylhydrolase Activity in Dyslipidemias of Type IIA and Type IIB. Tsimihodimos V, Karabina SP, Tambaki AP, Bairaktari E, Goudevenos JA, Chapman MJ, Elisaf M, Tselepis AD, Arterioscler Thromb Vasc Biol 2002 22 306 311 10.1161/hq0202.102918 11834533 (Pubitemid 34127044)
36. Alterations in the High Density Lipoprotein Phenotype and HDL-Associated Enzymes in Subjects with Metabolic Syndrome. Lagos KG, Filippatos TD, Tsimihodimos V, Gazi IF, Rizos C, Tselepis AD, Mikhailidis DP, Elisaf MS, Lipids 2008 44 9 16 18956219
37. Reduced HDL particle size as an additional feature of the atherogenic dyslipidemia of abdominal obesity. Pascot A, Lemieux I, Prud'homme D, Tremblay A, Nadeau A, Couillard C, Bergeron J, Lamarche B, Després JP, Lipid Res 2001 42 2007 2014 (Pubitemid 34001049)
38. High-density lipoprotein subclasses distribution and composition in Mexican adolescents with low HDL cholesterol and/or high triglyceride concentrations, and its association with insulin and c-reactive protein. Medina-Urrutia A, Juarez-Rojas JG, Martínez-Alvarado R, Jorge-Galarza E, Posadas-Sánchez R, Cardoso-Saldaña G, Caracas-Portilla N, Mendoza-Perez E, Posadas-Romero C, Atherosclerosis 2008 201 392 397 10.1016/j.atherosclerosis.2008.02.029 18420210
39. Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study. Tsimikas S, Willeit J, Knoflach M, Mayr M, Egger G, Notdurfter M, Witztum JL, Wiedermann CJ, Xu Q, Kiechl S, Eur Heart J 2009 30 107 115 19019993
40. Plasma Lp-PLA2 in acute coronary syndrome: association with major adverse cardiac events in a community-based cohort. Li N, Li S, Yu C, Gu S, Postgrad Med 2010 122 200 205 10.3810/pgm.2010.07.2187 20675983
41. Prognostic Utility of Lipoprotein-Associated Phospholipase A2 for Cardiovascular Outcomes in Patients With Stable Coronary Artery Disease. Sabatine MS, Morrow DA, O'Donoghue M, Jablonksi KA, Rice MM, Solomon S, Rosenberg Y, Domanski MJ, Hsia J, Arterioscler Thromb Vasc 2007 27 2463 2469 10.1161/ATVBAHA.107.151670 (Pubitemid 350203965)
42. Platelet-Activating Factor Acetylhydrolase Concentration in Children With Abdominal Obesity. Okada T, Miyashita M, Kuromori Y, Iwata F, Harada K, Hattori H, Arterioscler Thromb Vasc Biol 2006 26 40 e41 10.1161/01.ATV.0000217284. 86123.2c (Pubitemid 43732095)
43. Platelet-Activating Factor Acetylhydrolase (PAF-AH) Activity in Patients with Type 1 Diabetes Mellitus. Castro SH, Faria Neto HCC, Gomes MB, Arq Bras Cardiol 2007 88 179 184 10.1590/S0066-782X2007000200008 17384835 (Pubitemid 46481646)
44. Prevalence and Cluster of Cardiometabolic Biomarkers in Overweight and Obese Schoolchildren: Results from a Large Survey in Southwest Germany. Nagel G, Rapp K, Wabitsch M, Buchele G, Kroke A, Zollner I, Weiland SK, Koenig W, Clin Chem 2008 54 2317 2325
45. Lifestyle modification induced weight loss and changes of cardiometabolic risk factors including lowering of inflammatory response in obese children. Motykova E, Zlatohlavek L, Prusikova M, Lanska V, Ceska R, Vasickova L, Vrablik M, Neuro Endocrinol Lett 2011 32 Suppl 2 55 59 22101884
46. Platelet-Activating Factor Acetylhydrolase Is Not Associated with Carotid Intima-Media Thickness in Hypercholesterolemic Sicilian Individuals. Campo S, Sardo MA, Bitto A, Bonaiuto A, Trimarchi G, Bonaiuto M, Castaldo M, Saitta C, Cristadoro S, Saitta A, Clin Chem 2004 50 2077 2082 10.1373/clinchem.2004.036863 15364890 (Pubitemid 39425845)
47. Lipoprotein-Associated Phospholipase A2 and High-Sensitivity C-Reactive Protein Improve the Stratification of Ischemic Stroke Risk in the Atherosclerosis Risk in Communities (ARIC) Study. Nambi V, Hoogeveen RC, Chambless L, Hu Y, Bang H, Coresh J, Ni H, Boerwinkle E, Mosley T, Sharrett R, Folsom AR, Ballantyne CM, Stroke 2009 40 376 381 10.1161/STROKEAHA.107.513259 19095974